期刊文献+

非小细胞肺癌影像学分期与术后病理分期的对比研究 被引量:4

原文传递
导出
摘要 目的比较肺癌影像学分期与外科手术后病理分期,评价胸部CT检查在非小细胞肺癌术临床分期中的准确性。方法 90例接受胸部外科手术的病人,术前按照临床检查及CT影像结果进行临床分期CTNM。术后进行病理分期PTNM。结果 CT分期与病理分期符合度:I,Ⅱ期76.7%,ⅢA期74.4%,ⅢB期97.8%。Ⅰ,Ⅱ期敏感度78.4%、特异度75.4%,ⅢA期敏感度72%,特异度77.5%,ⅢB期敏感度66.7%,特异度98.6%;CT诊断肺门纵隔淋巴结转移的敏感度64.2%,特异度55.9%、准确度60.0%。结论胸部CT检查在非小细胞肺癌分期诊断上有较高的准确性,以CT检查结果为主的临床分期能为非小细胞肺癌临床治疗策略的制定提供主要依据,但对肺门纵隔淋巴结转移的CT诊断是以淋巴结短径的大小为依据的,与术后病理检查结果比较有一定的差异,敏感性、特异性均不高,应结合其他检查手段,比如联合PET或纵隔镜检查,以进行更精确的分期。
机构地区 丽水市人民医院
出处 《中国辐射卫生》 2011年第1期115-117,共3页 Chinese Journal of Radiological Health
  • 相关文献

参考文献9

二级参考文献22

  • 1吴一龙,戎铁华,黄植蕃,杨名添,曾灿光,傅剑华.肺癌临床TNM与病理TNM分期一致性的探讨[J].中华肿瘤杂志,1994,16(3):211-213. 被引量:7
  • 2Ogawa Mikako.^18F-FDG accumulation in atherosclerotic plaques:immunohistochemical and PET imaging study[J]. J Nucl Med,2004,45:1245-1250.
  • 3Vesselle H.In vivo alidation of 3' deoxy-3'-[^18F] fluorothymivdine ([^18F]FET) as a proliferation imaging tracer in human:correlation of [^18F]FET uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors[J].Clinical Cancer Research,2002,8:3315-3323.
  • 4Cerfolio RJ,Ojha B,Bryant AS,et al.The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer[J]. Ann Thorac Surg,2004,78:1017-1023.
  • 5Antoch G, Stattaus J, Nemat AT,et al.Non-small cell lung cancer:dual-modality PET/CT in preoperative staging[J].Radiology,2003,229:526-533.
  • 6Lardinosis D, Weder W, Hany TF,et al.Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography[J]. N Engl J Med,2003,19:348:2500-2507.
  • 7Bradley J, Thorstad WL, Mutic S,et al.Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2004,59:78-86.
  • 8Erdi YE, Rosenzweig K, Erdi AK,et al.Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography(PET)[J].Radiother Oncol,2002,62:51-60.
  • 9Raeter TP,Hellwig D,Hoffmann K,et al. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy[J].Ann Thorac Surg, 2003,75(1):231-235.
  • 10Gupta NC,Tamim WJ,Graeber GG. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging[J].Chest,2001,120(2):521-527.

共引文献193

同被引文献67

  • 1李泽坚.肺癌的现代外科治疗及存在的问题[J].中华医学杂志,2005,85(37):2595-2597. 被引量:7
  • 2臧琦,蒋仲敏,王伟,杨宜娥,朱强,王连生.肺癌胸腔积液CEA和CYFRA21-1及NSE术中联检的临床价值[J].中华肿瘤防治杂志,2006,13(17):1310-1312. 被引量:5
  • 3孙赞,孙世忠,翁亚贤,马庆宏,王玉芹,王兵,王忠刚.肺癌患者血清、胸水NSE、CYFRA21-1、CEA电化学发光方法联合检测的研究[J].辽宁医学杂志,2007,21(3):182-184. 被引量:1
  • 4刘泗军,干尧鳘,龙鸿川,石勇,阚奇伟.肺癌纵隔淋巴结转移分析[J].中国医药导报,2007,4(10Z):17-19. 被引量:3
  • 5Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? [J]. Thorac Dis, 2011,3 ( 1 ) : 19-29.
  • 6Koch A, Bergman B, Holmberg E, et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase 1I trial (CYCLUS study) by the Swedish Lung Cancer Study Group[J]. Eur J Cancer, 2011,47(10) : 1546-1555.
  • 7Mutter R,Lu B,Carbone DP,et al. A phase lI study of celecoxib in combination with paclitaxel,carboplatin, and radiotherapy for patients with inoperable stage 11I A/B non-small cell lung cancer [J]. Clin Cancer Res,2009,5(6) :2158-2165.
  • 8Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, enhances the response to preopera- tive paclitaxel and carboplatin in early-stage non small cell lung cancer[J]. J Clin Oncol,2003,21(14) :2645-2650.
  • 9Nugent FW, Mertens WC, Graziano S, et al. Docetaxel and cy- clooxygenase-2 inhibition with celecoxib for advanced non-small- cell lung cancer progressing after platinum-based chemotherapy: a multicancer phase II trial[J]. Lung Cancer, 2005,48 (2) : 267- 273.
  • 10Groen H J, Sietsma H, Vincent A, et al. Randomized, placebo-con- trolled phase m study of docetaxel plus carboplatin with celeeox- ib and cyclooxygenase-2 expression as a biomarker for patients with advanced non small cell lung cancer; the NVALT 4 study [J]. J Clin Oncol, 2011,9(32) :4320-4326.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部